Subscribe To
4 reasons goldman sachs is a buy
The renowned 153-year old investment bank is flexing its muscles in the consumer market and even explor...
April 2, 2022, 6:45 am
What makes uscb financial holdings, inc. (uscb) a new buy stock
uscB Financial Holdings, Inc. (uscB) has been upgraded t...
March 31, 2022, 1:33 pm
Psyched wellness unveils ‘calm' branding for its amanita muscaria extract
Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) Ltd has unveiled the official branding and visuals for its Amanita M...
March 30, 2022, 8:19 am
Bausch to reduce debt by another $200 million by repaying senior loans on march 31
Bausch Health Cos. Inc. BHC, -1.05% said Tuesday it will reduce its debt by $200 million by paying down...
March 29, 2022, 8:09 am
Bausch (bhc) up 1% since last earnings report: can it continue?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?...
March 25, 2022, 1:32 pm
Roche to present data across broad and impactful neuroscience portfolio at 2022 aan annual meeting
Basel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for its approved and investigational medicines across neurological ...
March 25, 2022, 2:00 am
Psyched wellness announces preliminary data from national research council of canada on neuroprotective properties of mushroom extract ame-1
Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) Ltd. has announced preliminary data from the National Research Council of Canada (NRC), from studies on the n...
March 24, 2022, 12:21 pm
Zimmer biomet: short-term issues, long-term growth opportunities
Zimmer Biomet ( ZBH , Financial) is a global leader in musculoskeletal health care. The company designs...
March 24, 2022, 11:54 am
Bausch health is waiting for 'appropriate market conditions' to complete spin-off, ceo says
CNBC's Jim Cramer spoke with Bausch Health CEO Joe Papa in Tuesday's edition of "Mad Money."...
March 22, 2022, 7:49 pm
Argenx's subcutaneous efgartigimod at par with intravenous administration in neuromuscular disorder
Argenx SE (NASDAQ: ARGX) ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized mya...
March 22, 2022, 12:30 pm
Anheuser-busch inbev is trapped below $71. should investors wait for a buy signal?
Anheuser-Busch InBev (EBR:ABI) has been trapped below MA 200 for extended periods. The crisis in Russia...
March 16, 2022, 5:59 pm
2 etfs to watch for outsized volume on china and commodity
FXI and uscI saw massive trading volumes in yesterday session....
March 16, 2022, 11:17 am
Investing club: what cramer is watching wednesday — fed's big meeting, bullish talk from bausch, boeing is 'fresh'
As the Fed is expected to lift interest rates today, inflation shows no sign of slowing in any commodity outside of oil....
March 16, 2022, 9:22 am
Immunitybio: extensive pipeline, nda expected for anktiva this quarter
BLA filing of Anktiva + BCG in BCG-unresponsive cancer in Situ non-muscle invasive bladder cancer patie...
March 15, 2022, 5:39 pm
Bausch health companies inc. (bhc) ceo joe papa presents at 2022 barclays global healthcare conference (transcript)
Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at 2022 Barclays Global Healthcare Conference ...
March 15, 2022, 2:32 pm
Novartis's data reinforces age-appropriate development with zolgensma gene therapy study
Novartis AG (NYSE: NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment fo...
March 14, 2022, 1:00 pm
Bridgebio pharma posts updated data from muscular dystrophy trial, plots path to market
BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle m...
March 14, 2022, 11:41 am
Scholar rock to present data from topaz ambulatory cohort analysis at the 2022 muscular dystrophy association (mda) clinical & scientific conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a poster presentation at the 2022 Muscular Dy...
March 13, 2022, 7:00 pm
Investors hoping for news at cancer meeting that will boost share prices
Given that developing biotechnology companies are more susceptible to swings in stock price than establ...
March 10, 2022, 5:30 pm
Roku's long-term focus is being overshadowed
A disappointing near-term outlook is obfuscating the company's long-term potential....
March 10, 2022, 10:15 am